Novo Nordisk ZEUS Trial: No MACE Benefit, HR 0.99
Novo Nordisk (NYSE:NVO) reported headline results from the phase 3 ZEUS cardiovascular outcomes trial of…
Novo Nordisk drug shows no MACE benefit in ZEUS trial | NVO SEC Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…